Literature DB >> 20217432

Elevated FGF-23 and parathormone in linear nevus sebaceous syndrome with resistant rickets.

Sidharth K Sethi, Pankaj Hari, Arvind Bagga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20217432     DOI： 10.1007/s00467-010-1485-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  7 in total

1.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

Authors:  Yuji Yamazaki; Ryo Okazaki; Minako Shibata; Yukihiro Hasegawa; Kohei Satoh; Toshihiro Tajima; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Takeyoshi Yamashita; Seiji Fukumoto
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

2.  Cinacalcet in the management of tumor-induced osteomalacia.

Authors:  Jordan L Geller; Azarmindokht Khosravi; Marilyn H Kelly; Mara Riminucci; John S Adams; Michael T Collins
Journal:  J Bone Miner Res       Date:  2007-06       Impact factor: 6.741

3.  Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome.

Authors:  William H Hoffman; Harald W Jueppner; Barry R Deyoung; M Sue O'dorisio; Keena S Given
Journal:  Am J Med Genet A       Date:  2005-04-30       Impact factor: 2.802

4.  The parathyroid is a target organ for FGF23 in rats.

Authors:  Iddo Z Ben-Dov; Hillel Galitzer; Vardit Lavi-Moshayoff; Regina Goetz; Makoto Kuro-o; Moosa Mohammadi; Roy Sirkis; Tally Naveh-Many; Justin Silver
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions.

Authors:  L C Aschinberg; L M Solomon; P M Zeis; P Justice; I M Rosenthal
Journal:  J Pediatr       Date:  1977-07       Impact factor: 4.406

6.  Regulation of fibroblast growth factor-23 in chronic kidney disease.

Authors:  Per-Anton Westerberg; Torbjörn Linde; Björn Wikström; Osten Ljunggren; Mats Stridsberg; Tobias E Larsson
Journal:  Nephrol Dial Transplant       Date:  2007-06-13       Impact factor: 5.992

7.  Increased in vitro bone resorption by monocytes in the hyper-immunoglobulin E syndrome.

Authors:  D Y Leung; L Key; J J Steinberg; M C Young; M Von Deck; R Wilkinson; R S Geha
Journal:  J Immunol       Date:  1988-01-01       Impact factor: 5.422
  7 in total
  9 in total

Review 1.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

Review 2.  FGF23 and Phosphate Wasting Disorders.

Authors:  Xianglan Huang; Yan Jiang; Weibo Xia
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

Review 3.  Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.

Authors:  D Ovejero; Y H Lim; A M Boyce; R I Gafni; E McCarthy; T A Nguyen; L F Eichenfield; C M C DeKlotz; L C Guthrie; L L Tosi; P S Thornton; K A Choate; M T Collins
Journal:  Osteoporos Int       Date:  2016-08-06       Impact factor: 4.507

Review 4.  Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.

Authors:  Bracha K Goldsweig; Thomas O Carpenter
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

5.  Linear nevus sebaceous syndrome with hypophosphatemic rickets with elevated FGF-23.

Authors:  Ryo Narazaki; Kenji Ihara; Noriyuki Namba; Hiroshi Matsuzaki; Keiichi Ozono; Toshiro Hara
Journal:  Pediatr Nephrol       Date:  2011-12-29       Impact factor: 3.714

6.  Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.

Authors:  Young H Lim; Diana Ovejero; Jeffrey S Sugarman; Cynthia M C Deklotz; Ann Maruri; Lawrence F Eichenfield; Patrick K Kelley; Harald Jüppner; Michael Gottschalk; Cynthia J Tifft; Rachel I Gafni; Alison M Boyce; Edward W Cowen; Nisan Bhattacharyya; Lori C Guthrie; William A Gahl; Gretchen Golas; Erin C Loring; John D Overton; Shrikant M Mane; Richard P Lifton; Moise L Levy; Michael T Collins; Keith A Choate
Journal:  Hum Mol Genet       Date:  2013-09-04       Impact factor: 6.150

Review 7.  FGF23 and Associated Disorders of Phosphate Wasting.

Authors:  Anisha Gohil; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2019-09

Review 8.  Fibroblast growth factor 23: state of the field and future directions.

Authors:  Nisan Bhattacharyya; William H Chong; Rachel I Gafni; Michael T Collins
Journal:  Trends Endocrinol Metab       Date:  2012-08-24       Impact factor: 12.015

Review 9.  Hypophosphatemic rickets due to perturbations in renal tubular function.

Authors:  Maria Goretti M G Penido; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2013-05-01       Impact factor: 3.714
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.